According to a large real-world study reported by ScienceDaily, researchers analyzing nearly 60,000 adults with type 2 diabetes have found an unexpected benefit of semaglutide—the active ingredient in Ozempic and Wegovy. While the medication delivers greater weight loss than other common treatments, users experienced about 15% fewer bone fractures. That's remarkable because weight loss typically increases fracture risk. The finding suggests semaglutide may protect bone density in ways beyond simply maintaining body weight.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton